SCHEMBL4112519

SCHEMBL4112519

CCOc1cccc(NC(=O)Nc2ccc(CC)cc2)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.78
NPC1 O15118 8/20 0.78
MAPT P10636 7/20 0.78
KMT2A Q03164 6/20 0.78
SMN1; SMN2 Q16637 5/20 0.78
MEN1 O00255 5/20 0.78
MITF O75030 1/20 0.62
PAX8 Q06710 1/20 0.62
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
HTT P42858 2/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
POLB P06746 2/20 0.53
PKM P14618 1/20 0.53
KDR P35968 1/20 0.53
MAPK14 Q16539 1/20 0.53
TNNI3K Q59H18 1/20 0.53
SAE1 Q9UBE0 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105128 0.90 MAPT (0.63) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4111978 0.90 NPC1 (0.75) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4112735 0.88 NPC1 (0.68) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4109903 0.87 RAB9A (0.64) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4105155 0.87 MAPT (1.00) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4107028 0.87 SMN1; SMN2 (0.64) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4106147 0.86 KMT2A (0.64) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4106738 0.86 NPC1 (0.64) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4121436 0.86 TSHR (0.78) RAB9ANPC1MAPTKMT2ASMN1; SMN2
SCHEMBL4117508 0.86 MAPT (0.70) RAB9ANPC1MAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 RAB9A 815/4885NPC1 927/4885MAPT 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.